Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Pediatr Res ; 87(4): 767-772, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31645056

RESUMO

BACKGROUND: Most neonatal outcomes in neonates are related to normal adrenal gland function. Assessment of adrenal function in a sick preterm neonate remains a challenge, thus we hypothesized that adrenal steroid precursors to their product ratios have a direct relationship with neonatal outcomes. METHODS: We studied demographics of pregnancy and neonatal outcomes in 99 mother-infant pairs (24-41 weeks) and assayed 7 glucocorticoid precursors in the cortisol biosynthesis/degradation pathway. We correlated antenatal factors and short-term neonatal outcomes with these precursors and their ratios to assess maturity of individual enzymes. RESULTS: We found no correlation between cortisol levels with antenatal factors and outcomes. Antenatal steroid use impacted several cortisol precursors. 17-OH pregnenolone-to-cortisol ratio at birth was the best predictor of short-term neonatal outcomes, such as hypotension, RDS, IVH and PDA. A cord blood 17-OH pregnenolone:cortisol ratio of <0.21 predicts which neonate will have a normal outcome with a high sensitivity and specificity. CONCLUSIONS: Maternal factors and antenatal steroids impact neonatal adrenal function and leads to maturation of adrenal function. 17-OH pregnenolone:cortisol ratio and not cortisol is the best predictor of adrenal function. Adrenal function can be assessed by evaluating the profile of adrenal steroids.


Assuntos
17-alfa-Hidroxipregnenolona/sangue , Testes de Função do Córtex Suprarrenal , Glândulas Suprarrenais/metabolismo , Hidrocortisona/sangue , Glândulas Suprarrenais/crescimento & desenvolvimento , Fatores Etários , Biomarcadores/sangue , Desenvolvimento Infantil , Feminino , Humanos , Recém-Nascido , Valor Preditivo dos Testes , Gravidez , Prognóstico , Estudos Prospectivos , Fatores de Tempo
2.
Transfusion ; 42(9): 1123-6, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12430667

RESUMO

BACKGROUND: WBC reduction of blood components may reduce the incidence of transfusion reactions. The cost of this intervention might be offset by a reduction in the incidence of postoperative infection, thereby reducing the length of hospital stay and thus the cost of care for patients receiving transfusion. Cedars-Sinai Medical Center provided WBC-reduced blood components to all patients for a period of 2 years, creating an opportunity to compare the incidence of postoperative infection, length of hospital stay, and total hospital costs for patients undergoing coronary artery bypass graft surgery, before, during, and after WBC reduction. STUDY DESIGN AND METHODS: Data were obtained by examining hospital records of patients who received transfusion and control patients who did not receive transfusion for the years 1991 (before WBC reduction), 1992 to 1993 (during WBC reduction), and 1994 (following discontinuation of WBC reduction). Comparisons were made by use of ANOVA following log or square root transformation of the data. RESULTS: Length of hospital stay for patients who received transfusion decreased over time. Mean hospital stays were 15.9, 14.1, and 12.1 days before, during, and after WBC reduction, respectively. A similar trend was seen in the patients who did not receive transfusion. There was no indication that WBC reduction functioned as an independent variable that was responsible for the observed decrease. The rate of postoperative infection stayed constant during WBC reduction and only dropped when WBC reduction was stopped. Mean hospital cost showed no significant change over time for either the transfusion group or the nontransfusion group. CONCLUSION: The cost of providing a totally WBC-reduced blood supply may not be offset by immediate savings related to decreased postoperative infections, reduced length of hospital stay, and cost of hospital care.


Assuntos
Transfusão de Componentes Sanguíneos/economia , Ponte de Artéria Coronária/economia , Custos Hospitalares , Leucócitos , Idoso , Idoso de 80 Anos ou mais , Transfusão de Componentes Sanguíneos/efeitos adversos , Transfusão de Sangue/economia , Estudos de Casos e Controles , Feminino , Humanos , Terapia de Imunossupressão , Infecções/epidemiologia , Tempo de Internação/economia , Tempo de Internação/estatística & dados numéricos , Los Angeles , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Estudos Retrospectivos , Reação Transfusional
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA